Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.
Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Hawkins RE, Crinò L, Kim TM, Carteni G, Eberhardt WE, Zhang K, Fly K, Matczak E, Lechuga MJ, Hariharan S, Bukowski R. Gore ME, et al. Among authors: haanen j. Br J Cancer. 2015 Jun 30;113(1):12-9. doi: 10.1038/bjc.2015.196. Epub 2015 Jun 18. Br J Cancer. 2015. PMID: 26086878 Free PMC article.
Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study.
Kerst JM, Bex A, Mallo H, Dewit L, Haanen JB, Boogerd W, Teertstra HJ, de Gast GC. Kerst JM, et al. Among authors: haanen jb. Cancer Immunol Immunother. 2005 Sep;54(9):926-31. doi: 10.1007/s00262-005-0677-2. Epub 2005 May 19. Cancer Immunol Immunother. 2005. PMID: 15906025 Free PMC article. Clinical Trial.
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.
van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, Hoekman K, de Gruijl TD. van Cruijsen H, et al. Among authors: haanen jb. Clin Cancer Res. 2008 Sep 15;14(18):5884-92. doi: 10.1158/1078-0432.CCR-08-0656. Clin Cancer Res. 2008. PMID: 18794101
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R. Gore ME, et al. Among authors: haanen j. Lancet Oncol. 2009 Aug;10(8):757-63. doi: 10.1016/S1470-2045(09)70162-7. Epub 2009 Jul 15. Lancet Oncol. 2009. PMID: 19615940 Clinical Trial.
Myelosuppression by sunitinib is flt-3 genotype dependent.
van Erp NP, Mathijssen RH, van der Veldt AA, Haanen JB, Reyners AK, Eechoute K, Boven E, Wessels JA, Guchelaar HJ, Gelderblom H. van Erp NP, et al. Among authors: haanen jb. Br J Cancer. 2010 Aug 24;103(5):757-8. doi: 10.1038/sj.bjc.6605813. Epub 2010 Aug 3. Br J Cancer. 2010. PMID: 20683446 Free PMC article. No abstract available.
470 results